Regulatory PathRegulatory requirements compared

Active substance

Colistin

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
COLY-MYCIN SEQ 25MG BASE/5MLsuspension · oralPARKE DAVISDiscontinued

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
COLISTIMETHATE FOR INJECTION U.S.P.02244849150 MG / VIALPOWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULARSTERIMAX INC
COLISTIMETHATE FOR INJECTION, USP02403544150 MG / VIALPOWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULARFRESENIUS KABI CANADA LTD
COLY-MYCIN M00476420150 MG / VIALPOWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUSSEARCHLIGHT PHARMA INC

WHO WHO Model List of Essential Medicines (2025)

  • 6.2.3. Reserve group antibiotics · complementary
    Carbapenem resistant Acinetobacter baumannii; Carbapenem-resistant Pseudomonas aeruginosa; Other carbapenem resistant Enterobacterales; Carbapenem resistant Klebsiella pneumoniae; Carbapenem resistant Escherichia coli
    Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)

Safety signals and safety-related labeling changes

All safety entries for colistin →

Combinations containing Colistin

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.